Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from EQS Group

00:56 EDT 20th June 2019 | BioPortfolio

Here are the most relevant search results for "EQS Group" found in our extensive news archives from over 250 global news sources.

More Information about EQS Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about EQS Group for you to read. Along with our medical data and news we also list EQS Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of EQS Group Companies for you to search.

Showing News Articles 1–25 of 1,000+ from EQS Group

Wednesday 19th June 2019

RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2019 OF EVOTEC SE

DGAP-News: Evotec SE / Key word(s): AGM/EGM 19.06.2019 / 17:26 The issuer is solely responsible for the content of this announcement. APPROVAL OF ALL AGENDA ITEMS NEW SUPERVISORY BOARD ELECTED Hamburg, Germany, 19 June 2019: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Manageme...

MOLOGEN AG: Announcement to holders of the EUR 4.999.990,00 worth of convertible bonds maturing in 2025 (the convertible bonds) (ISIN: DE000A2DANN4, SIN A2DANN)

DGAP-News: MOLOGEN AG / Key word(s): Bond 19.06.2019 / 15:04 The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Mologen AG Berlin Announcement to holders o...

Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer

Polyphor AG / Key word(s): Study 19-Jun-2019 / 07:07 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 19, 2019 Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic b...

Tuesday 18th June 2019

CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution

DGAP-News: CENTOGENE AG / Key word(s): Miscellaneous 18.06.2019 / 16:10 The issuer is solely responsible for the content of this announcement. CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution Variant Prioritization Tool Driven by World's Largest Curated Mutation Database Cambridge, MA USA & Rostock, Berlin GERMANY, 18 June, 2019. In a whitepap...

Vivoryon Therapeutics AG: Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Agreement 18.06.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology     HALLE (SAALE) and MUNICH, Germany, 18 June 2019 - Vivoryon The...

Monday 17th June 2019

Epigenomics AG: New Clinical Data Support the Utility of Epi proColon(R) Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

DGAP-News: Epigenomics AG / Key word(s): Study results/Scientific publication 17.06.2019 / 14:00 The issuer is solely responsible for the content of this announcement. New Clinical Data Support the Utility of Epi proColon Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome   Minimally-invasive blood test ...

MetrioPharm AG: Last Patient Last Visit in MetrioPharm's Phase II Clinical Trial in Psoriasis

EQS Group-News: MetrioPharm AG / Key word(s): Study 17.06.2019 / 13:25   - The last psoriasis patient underwent final medical examinations on June 12th 2019 - MetrioPharm still content with safety profile of lead compound MP 1032 - Starting the data cleaning with subsequent analysis Zurich, June 17, 2019. MetrioPharm AG, a pharmaceutical development company, announces that the l...

CO.DON AG: successful Annual General Meeting 2019

DGAP-News: CO.DON AG / Key word(s): AGM/EGM 17.06.2019 / 11:00 The issuer is solely responsible for the content of this announcement. CO.DON: successful Annual General Meeting 2019 Teltow/Berlin, 17.06.2019 - This year's annual general meeting of CO.DON AG (ISIN DE000A1K0227) took place in Berlin on 12 June 2019 and was chaired by Professor Hans Bauerfeind, the Chairman of the Supervi...

Friday 14th June 2019

Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call

Northvale, 06/14/2019 / 16:00, EST/EDT - EQS Newswire - Elite Pharmaceuticals, Inc. Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call NORTHVALE, NJ / ACCESSWIRE / June 14, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB: ELTP), announced today that it has delayed its previously announced earnings release and c...

MOLOGEN AG: Announcement to holders of the EUR 2,707,050.00 worth of convertible bonds maturing in 2027 (the convertible bonds) (ISIN: DE000A2NBMN3, SIN A2NBMN)

DGAP-News: MOLOGEN AG / Key word(s): Bond 14.06.2019 / 15:17 The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Mologen AG Berlin Announcement to holders of ...

MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 14.06.2019 / 13:58 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, June 14, 2019 MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis   MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nas...

Thursday 13th June 2019

DGAP-DD: STRATEC SE english

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.06.2019 / 18:05 The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated a) Name Title: First name: Ma...

CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia

DGAP-News: CENTOGENE AG / Key word(s): Study 13.06.2019 / 14:00 The issuer is solely responsible for the content of this announcement. CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia Research findings may provide deeper understanding on the role of genes that can contribute to development of Hypophosphatasia Cambridge, MA USA & Rostock, GERMANY, 13 J...

Wednesday 12th June 2019

Biofrontera AG: Biofrontera to Present at Two Upcoming Investor Conferences

DGAP-News: Biofrontera AG / Key word(s): Conference 12.06.2019 / 17:00 The issuer is solely responsible for the content of this announcement. Biofrontera to Present at Two Upcoming Investor Conferences Leverkusen, Germany, June 12, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that Thomas...

ADC Therapeutics Announces Completion of a Series E Financing Expansion

EQS Group-News: ADC Therapeutics SA / Key word(s): Financing 12.06.2019 / 12:00 ADC Therapeutics Announces Completion of a Series E Financing Expansion   Brings total raised in the Series E round to $276 million Lausanne, Switzerland, June 12, 2019 - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugate...

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma

EQS Group-News: ADC Therapeutics SA / Key word(s): Conference 12.06.2019 / 11:55 ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma   Three oral presentations and one poster presentation Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents a...

Expedeon AG: Expedeon AG mandates ODDO SEYDLER BANK AG as Designated Sponsor (news with additional features)

DGAP-News: Expedeon AG / Key word(s): Miscellaneous 12.06.2019 / 08:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE 12 June 2019 Expedeon AG mandates ODDO SEYDLER BANK AG as Designated Sponsor   Heidelberg, Germany and Cambridge, UK, 12 June 2019 - ODDO SEYDLER BANK AG will henceforth be the second Designated Sponsor of Expedeon AG's shar...

Probiodrug AG becomes Vivoryon Therapeutics AG

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Corporate Action 12.06.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Probiodrug AG becomes Vivoryon Therapeutics AG Healthy Aging - Pioneering Innovation HALLE (SAALE), Germany, 12 June 2019 - Probiodrug AG (Euronext Amsterdam: currently PBD, to be changed to VVY, ISIN: DE0007921835), focusing on t...

Tuesday 11th June 2019

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-end Financial Results on June 17, 2019

Northvale, 06/11/2019 / 09:49, EST/EDT - EQS Newswire - Elite Pharmaceuticals, Inc. Financials for Fiscal Year Ended March 31, 2019 will be released June 14, 2019 NORTHVALE, NJ / ACCESSWIRE / June 11, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, an...

Annual General Meeting of ifa systems AG

DGAP-News: ifa systems AG / Key word(s): AGM/EGM 11.06.2019 / 11:15 The issuer is solely responsible for the content of this announcement. Annual General Meeting of ifa systems AG Annual General Meeting approves all resolutions by a large majority Management Board sees ifa back on track for success after realignment Positive general mood after the entry of the new majority sharehol...

4SC AG resolves to issue new shares to continue to advance its drug development programs for resminostat and domatinostat

4SC AG / Key word(s): Corporate Action 4SC AG resolves to issue new shares to continue to advance its drug development programs for resminostat and domatinostat 11-Jun-2019 / 09:31 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this ...

Heidelberg Pharma AG Presents Proprietary ATAC Technology Platform at Two Scientific Conferences

DGAP-News: Heidelberg Pharma AG / Key word(s): Conference 11.06.2019 / 07:19 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences Ladenburg, Germany, 11 June 2019 - Heidelberg Pharma AG (FWB: WL6) today announced that they will present their proprietary techno...

Monday 10th June 2019

EVOTEC RECEIVES $ 23.8 M GRANT TO JOIN THE GLOBAL FIGHT AGAINST TUBERCULOSIS

DGAP-News: Evotec SE / Key word(s): Miscellaneous 10.06.2019 / 19:30 The issuer is solely responsible for the content of this announcement. THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC WITH A $ 23.8 M GRANT TO GENERATE CRITICAL DATA FOR SELECTING BEST DRUG COMBINATIONS FOR PHASE II CLINICAL TRIALS TUBERCULOSIS IS THE LEADING CAUSE OF DEATH DUE TO AN INFECTIOUS DISEASE WORL...

PAION AG: FDA ACCEPTS FILING OF NDA FOR REMIMAZOLAM IN THE U.S.

DGAP-News: PAION AG / Key word(s): Research Update 10.06.2019 / 10:37 The issuer is solely responsible for the content of this announcement. FDA ACCEPTS FILING OF NDA FOR REMIMAZOLAM IN THE U.S. Aachen (Germany), 10 June 2019 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces, that its U.S. remimazolam licensee Cosmo Phar...

Friday 7th June 2019

MagForce AG and the Paracelsus Clinic Zwickau announce cooperation agreement and the opening of a new NanoTherm treatment center

DGAP-News: MagForce AG / Key word(s): Alliance/Agreement 07.06.2019 / 12:00 The issuer is solely responsible for the content of this announcement. MagForce AG and the Paracelsus Clinic Zwickau announce cooperation agreement and the opening of a new NanoTherm treatment center With the treatment center at the Paracelsus Clinic in Zwickau another geographically important location will s...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks